Cartalax for Health & Longevity

Evidence Review created on 09/01/2026 using AI4L / Opus 5

Also known as: AED, Ala-Glu-Asp, Alanyl-Glutamyl-Aspartic Acid, Kartalax, T-31, Cartilage Peptide Bioregulator

Motivation

Cartalax is a laboratory-made peptide built from three amino acids, the small building blocks that make up proteins. It was designed in Russia as a messenger aimed at cartilage and the connective tissue around joints, and it is meant to work by nudging cells back toward a younger pattern of activity rather than by blocking a receptor or replacing a hormone.

It belongs to a family of very short peptides that grew out of Soviet-era work with extracts from animal organs, later reduced to synthetic copies of their smallest active fragments. Cartalax is the synthetic counterpart of the cartilage extract in that line. Nearly all published work on it comes from one institute in St. Petersburg, and outside Russia it is sold as a research chemical rather than as an approved medicine.

This review examines what is actually known about Cartalax: how it is proposed to act on joint tissue, what the published experiments measured and in which systems, what has never been tested in people, and what the sourcing and quality questions are.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

High-level material that explains Cartalax itself or the class of ultrashort synthetic peptides it belongs to.

• Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation - Myakisheva et al., 2023

  Names Cartalax explicitly and traces how the aging secretory phenotype of chondrocytes (cartilage cells) drives osteoarthritis, then argues for peptide chondroprotection; written by the institute that developed and sells the compound.

• #403 ‒ Peptides: separating scientific promise from marketing hype - Peter Attia

  Gives a framework for judging any short synthetic peptide sold outside approved channels, the exact category Cartalax occupies, separating peptides with regulatory approval from those with none.

• Peptides: The Science, Uses & Safety – Dr. Abud Bakri - Andrew Huberman

  Covers sourcing, purity and safety for consumer peptides, and discusses epitalon, another synthetic Khavinson short peptide built on the same DNA-binding rationale Cartalax relies on.

• A Global Review on Short Peptides: Frontiers and Perspectives - Apostolopoulos et al., 2021

  An independent, non-Russian survey of short peptides as a therapeutic class, giving an outside benchmark for the claims made for Cartalax and other ultrashort bioregulators.

Only four items are listed. No fifth source met the bar: Cartalax is absent from every priority expert platform, and the remaining material found in searches consisted of vendor product pages, encyclopedia entries and reseller blogs, all of which are excluded here rather than used as padding.

Grokipedia

No Grokipedia article exists for Cartalax. A direct search of grokipedia.com returned no results for either “Cartalax” or the alternate spelling “Kartalax”.

Examine

No Examine article exists for Cartalax. A direct search of examine.com returned no results.

ConsumerLab

No ConsumerLab article exists for Cartalax. A direct search of consumerlab.com returned no results, which is consistent with ConsumerLab testing retail dietary supplements rather than research-grade peptides.

Systematic Reviews

The systematic review literature that touches Cartalax directly, retrieved from PubMed.

• Peptide Regulation of Gene Expression: A Systematic Review - Khavinson et al., 2021

  Systematically maps how ultrashort peptides, AED (Cartalax) included, alter gene expression; authored by the institute that develops and sells them, a direct commercial interest.

Cartalax involves a trade-off between an unproven cartilage benefit and the hazards of an unlicensed product. Only the benefit side is represented in the systematic review literature. No systematic review or meta-analysis addresses the safety, toxicology, or harms of Cartalax or of the AED tripeptide, so the risk side of the trade-off is unrepresented here.

Mechanism of Action

Cartalax is the tripeptide alanyl-glutamyl-aspartic acid (Ala-Glu-Asp), molecular weight roughly 333 daltons. The proposed mechanism is epigenetic rather than receptor-mediated. Peptides this small can cross the cell and nuclear membranes, bind in the minor groove of double-stranded DNA at adenine- and thymine-rich stretches, and bind histones, the spool proteins that DNA is wound around, altering which gene promoters are available for transcription (Khavinson et al., 2021).

In aged cell cultures this is reported to raise SOX9 (the master transcription switch for cartilage-cell identity), aggrecan and type II collagen (the two load-bearing components of cartilage), and COMP (cartilage oligomeric matrix protein, a structural connector within cartilage) (Myakisheva et al., 2023), while lowering p16 and p21 (proteins that lock aged cells out of division) (Myakisheva et al., 2023).

A competing mechanistic reading exists. No receptor or transporter specific to Cartalax has been identified, a three-residue sequence carries little unique sequence information, and the observed effects may simply reflect the delivery of free amino acids after hydrolysis. Neither reading has been tested against the other in an animal or human system.

Pharmacological properties are unestablished. There is no published human pharmacokinetic study, so selectivity and tissue distribution have never been measured. Tripeptides are hydrolysed at the intestinal brush border and by plasma and tissue aminopeptidases, implying a plasma half-life of minutes rather than hours (Rohm et al., 2019). Metabolism is peptidase-mediated hydrolysis to alanine, glutamate and aspartate; no cytochrome P450 pathway (the liver’s main drug-processing enzyme family) is involved.

Historical Context & Evolution

Cartalax descends from a Soviet military-medicine programme begun in the 1970s at what became the St. Petersburg Institute of Bioregulation and Gerontology. The original intent was not longevity but recovery: extracts of calf organs, termed cytomedines, were given to restore function in irradiated and stressed personnel, on the premise that each tissue contains its own regulatory peptides. Cartilage and bone extract entered that line as the preparation later marketed as Sigumir.

The move to health optimization came when the extracts were fractionated and their smallest active fragments synthesised. Investigators reported that the isolated tri- and tetrapeptides reproduced the tissue-selective effects of the parent extracts at nanogram concentrations, with a larger effect in aged cultures (Khavinson et al., 2012). Cartalax is the tripeptide assigned to the cartilage extract. The findings are specific: the extracts raised proliferation markers and lowered p53 (a protein that halts damaged cells) (Ryzhak et al., 2015), and the tripeptide later restored cartilage-matrix gene expression in aged cultures.

Scientific opinion outside Russia has not converged. The critique is that the work is concentrated in one institute with a commercial stake, published largely in Russian-language journals, and rarely reproduced independently. The counterweight is that Italian groups have reported senescence-marker effects for peptides in this family, though the developing institute co-authored that work (Sinjari et al., 2020), and that no group has published a failed replication either. What changed over fifty years is the resolution of the endpoints, not the arrival of a decisive human trial in either direction.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the available evidence class is cell-culture gene expression and protein staining in aged cell lines, and no controlled human trial has measured a clinical endpoint or a validated clinical surrogate for Cartalax even once, let alone more than once.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single controlled human trial and no consistent observational human dataset for Cartalax; the only human evidence class is uncontrolled clinical experience described secondhand in a review article.

Low 🟩

Symptom Relief in Age-Related Osteoarthritis

The claimed benefit is relief of joint pain and stiffness in age-related osteoarthritis. The evidence basis is a narrative review from the developing institute reporting oral use in older patients; no trial identifier, sample size, comparator or outcome measure accompanies it.

Magnitude: Not quantified in available studies. The only human report is a secondhand summary that names no outcome measure and identifies no underlying trial, so no pain or function figure exists to cite.

Speculative 🟨

Chondrogenic Matrix Gene Activation in Aging Stem Cells

At 200 nanograms per millilitre, Cartalax raised cartilage-matrix gene expression and protein synthesis in replicatively aged human mesenchymal stem cells, the body’s connective-tissue progenitors. Basis is cell culture only (Myakisheva et al., 2023).

Senescence-Marker Normalization in Aging Chondrocyte and Kidney Cultures

In aged chondrocyte cultures, Cartalax lowered p16, p21 and p53 while restoring sirtuin-1 (a longevity-linked repair enzyme) (Myakisheva et al., 2023); aged kidney cells matched that, raising sirtuin-6 (Khavinson et al., 2014). Cell culture only.

Dermal Collagen and Sirtuin Activation in Aging Fibroblasts

Cartalax raised type I collagen and sirtuins 1 and 6 in aging human skin fibroblasts (Fridman et al., 2020). It also suppressed matrix metalloproteinase-9 (a collagen-degrading enzyme) (Lin’kova et al., 2016).

Neuronal Differentiation Support

Combined with related short peptides, Cartalax increased nestin and GAP-43 (two markers of early nerve-cell commitment) in human periodontal ligament stem cells (Caputi et al., 2019). Effect not isolated to Cartalax alone.

Benefit-Modifying Factors

• Peptide transporter and peptidase activity: Oral use depends on SLC15A1 (PEPT1, the gut transporter carrying intact tripeptides across the intestinal wall). Peptides beginning with a small residue such as alanine are preferentially broken down instead, so absorption of intact Cartalax is likely poor.

• Genetic polymorphisms: No variant is established as modifying Cartalax benefit. SLC15A1 (PEPT1) polymorphisms that reduce intestinal peptide transport would in theory lower oral exposure, and with it any matrix-anabolic effect, but this has never been tested for a Khavinson peptide.

• Baseline cartilage turnover: Any matrix-anabolic effect has more room to show where turnover markers indicate active cartilage breakdown. In joints where cartilage is already absent and bone contacts bone, no proposed mechanism of Cartalax applies.

• Sex-based differences: None have been studied. No published experiment reports results separately by donor sex, and no animal work compares male and female responses, so any sex difference in benefit is currently unknown rather than absent.

• Pre-existing health conditions: The proposed benefit targets degenerative osteoarthritis. Inflammatory arthritis, crystal arthropathy (gout and related joint crystal diseases) and post-traumatic cartilage defects have different drivers, and no data suggest Cartalax addresses them.

• Age-related considerations: Every reported effect was larger in replicatively aged cultures than in young ones, so the proposed benefit is, if real, biased toward older users. That same pattern means younger adults have the weakest theoretical case.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the available evidence class is in-vitro gene and protein assays plus market-surveillance product analyses; no controlled human trial of Cartalax has documented an adverse event, and no post-marketing safety database covers it.

Medium 🟥 🟥

No risk reaches Medium either: no single controlled human trial and no consistent observational dataset report adverse events for Cartalax; the evidence class stops at cell culture and at indirect product-quality analysis of the same supply channel.

Low 🟥

Substandard, Contaminated or Misdosed Product

Cartalax reaches buyers only through the prescription-free online peptide channel. Laboratory analysis of test purchases from that channel found grossly overstated purity and bacterial endotoxin in every vial (Ashraf et al., 2024). The hazard is the vial contents, not the tripeptide.

Magnitude: In that test-purchase analysis, measured purity was 7.7–14.37% against a 99% label claim, and endotoxin (a bacterial cell-wall toxin that provokes fever and inflammation) was detected in all samples at 2.16–8.95 endotoxin units per milligram.

Bypassed Clinical Oversight and Delayed Diagnosis

Vials sold “for research purposes only” arrive without a prescriber or pharmacist in the loop, so no one screens for interactions, verifies technique, or arranges follow-up (Belcourt et al., 2025). Self-treated joint pain can mask septic or inflammatory arthritis.

Magnitude: The direction is toward more harm as self-sourcing replaces clinical assessment, and the risk concentrates where new joint pain is assumed to be wear-and-tear; the pharmacy-practice literature reports no outcome figure for this pathway.

Speculative 🟨

Growth-Factor Signalling in Undetected Cancer

In aged stem cell cultures, the peptides tested including Cartalax raised IGF-1 (insulin-like growth factor 1, a growth-signalling hormone) gene expression 3.5- to 5.6-fold (Ashapkin et al., 2020). Concern is mechanistic only.

Sustained NF-κB Activation ⚠️ Conflicted

Cartalax raised NF-κB (a master inflammatory switch) in stem cells (Ashapkin et al., 2020) yet lowered inflammatory signals in chondrocytes (Myakisheva et al., 2023). Net reading: the direction is cell-type dependent and unresolved.

Injection-Site Reactions and Sterile-Technique Failure

Users reconstitute freeze-dried powder themselves and inject subcutaneously without training. Redness, nodules and local infection are the expected hazards. No incidence figure exists for Cartalax; the basis is isolated reports from this supply channel.

Risk-Modifying Factors

• Genetic polymorphisms: No pharmacogenetic variant is known to modify Cartalax risk. Variation in SLC15A1 (PEPT1), the intestinal peptide transporter, would alter oral exposure in theory, but no study has measured this for any Khavinson peptide.

• Baseline biomarker levels: An elevated baseline IGF-1 or an unexplained inflammatory marker raises the stakes of adding a compound that stimulates growth signalling in culture, because neither can be attributed to the peptide afterward without a pre-treatment value.

• Sex-based differences: No sex-stratified safety data exist for Cartalax. Pregnancy and lactation are untested entirely, so no statement about relative risk between men and women is currently supportable in either direction.

• Pre-existing health conditions: Active or recently treated malignancy is the condition where the theoretical growth-signalling risk matters most. Immunosuppression raises the consequence of an endotoxin-contaminated or non-sterile injection from a hazard to a serious one.

• Age-related considerations: Older adults carry more undiagnosed cancer and more joint pain from causes other than osteoarthritis, so both the theoretical proliferation risk and the misdiagnosis risk rise with age, exactly where the claimed benefit is largest.

Key Interactions & Contraindications

• Prescription growth-signalling agents: No documented interaction. Theoretical additive effect with growth hormone (somatropin) and IGF-1 analogues (mecasermin). Severity: caution. Consequence: compounded growth-factor signalling. Mitigation: courses not run concurrently.

• Prescription immunosuppressants: No documented interaction. With agents such as methotrexate, tacrolimus or prednisone, severity is caution because a contaminated injection carries far greater consequence: systemic infection. Mitigation: verified sterile product and aseptic technique.

• Over-the-counter analgesics: No documented interaction with non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) or paracetamol. Severity: monitor only. Consequence: symptom masking may hide progression. Mitigation: a written record of analgesic use across the course.

• Supplement interactions: No documented interaction with any supplement. Severity: monitor. Consequence: attribution failure, where an effect from a co-started supplement is credited to Cartalax. Mitigation: one variable changed at a time.

• Supplements with additive effects: Collagen peptides, undenatured type II collagen, glucosamine and chondroitin all target cartilage matrix. Severity: caution. Consequence: benefit cannot be attributed to either agent. Mitigation: start dates separated by at least eight weeks.

• Other intervention interactions: Intra-articular corticosteroid and hyaluronic acid injections share the injection site and recovery window. Severity: caution. Consequence: confounded assessment and additive infection risk. Mitigation: at least four weeks between injected interventions.

Populations who should avoid Cartalax:

• Anyone with active malignancy, or in remission for under five years, given the unresolved growth-signalling signal in culture.

• Anyone pregnant or breastfeeding: no reproductive or developmental toxicology exists for this compound at any dose.

• Anyone immunocompromised, including transplant recipients on maintenance immunosuppression and those with an absolute neutrophil count below 1,000 cells per microlitre.

• Anyone with a suspected septic joint, an unexplained fever, or new joint pain with swelling that has not been evaluated.

• Anyone with severe hepatic impairment (Child-Pugh Class C) or severe kidney impairment (estimated glomerular filtration rate under 30 millilitres per minute per 1.73 square metres), where no elimination data exist.

Risk Mitigation Strategies

• Third-party certificate of analysis: A batch-specific certificate showing mass-spectrometric identity, purity above 98%, and endotoxin below 0.5 endotoxin units per milligram directly addresses the substandard and contaminated product risk.

• Baseline evaluation before any course: An established diagnosis, with baseline inflammatory markers and imaging recorded before starting, mitigates the delayed-diagnosis risk, in which self-treatment masks septic or inflammatory arthritis for weeks.

• Aseptic reconstitution and single-use technique: Bacteriostatic water, an alcohol-swabbed vial septum, one sterile needle per injection, and reconstituted solution held at 2–8°C for no more than 30 days prevent injection-site infection.

• Short, bounded courses with washout: Courses limited to 10–20 days with at least three months between them bound total exposure, limiting the duration of the unresolved growth-signalling and NF-κB concerns.

• Cancer screening currency before starting: Age-appropriate screening current within the prior 12 months addresses the theoretical risk of stimulating growth signalling in an undetected malignancy.

• Stop rules defined in advance: Predefined discontinuation for fever, spreading injection-site redness, or new joint swelling, with assessment within 24 hours, converts the infection risk from an unnoticed hazard into a managed one.

Therapeutic Protocol

• Injectable course: Protocols in circulation, none from a published trial, describe 1–2 mg of reconstituted Cartalax subcutaneously once daily for 10–20 consecutive days, repeated two to three times per year.

• Competing approach, oral polypeptide complex: The cartilage extract Sigumir, taken as capsules for 30 days, is the alternative within the same tradition. Neither the extract nor the synthetic tripeptide has been compared against the other.

• Competing approach, conventional care: Progressive loading exercise, weight management and, where indicated, intra-articular injection remain the alternative outside this tradition. This review does not treat either approach as the default comparator.

• Attribution of the approach: Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology developed and popularised both the extract and the synthetic tripeptide. That institute also commercialises them, a direct financial interest in the protocols it publishes.

• Best time of day: No chronobiological data exist for Cartalax. Circulating protocols favour morning dosing on an empty stomach, which is convention rather than evidence, and no trial has compared morning with evening administration.

• Half-life and its consequence: The expected plasma half-life is minutes, since aminopeptidases hydrolyse tripeptides rapidly. Daily dosing therefore cannot maintain plasma exposure and instead assumes a pulse-and-persist effect on gene expression.

• Single versus split dosing: No comparison exists. Circulating protocols use a single daily dose. A split schedule has no supporting rationale given that the proposed effect is transcriptional rather than concentration-dependent at steady state.

• Genetic polymorphisms influencing dose: None are established. SLC15A1 (PEPT1) variants would in theory alter oral exposure, and APOE4 (a lipid-transport gene variant tied to age-related decline) has been discussed for related peptides, but neither has been tested here.

• Sex-based differences in response: None have been characterised. No published experiment reports donor sex, and no dose adjustment by sex has any evidential basis, so protocols in circulation are identical for men and women.

• Age-related considerations: Reported effects were larger in aged cells, and circulating protocols make no dose reduction for older adults. Adults over 75 carry greater infection consequence from self-injection, which argues for the oral route instead.

• Baseline biomarker levels: Circulating protocols specify no biomarker gating. Establishing inflammatory markers and cartilage turnover markers before starting is what makes any later change interpretable, since the effect size expected is unknown.

• Pre-existing conditions influencing response: Advanced joint space loss leaves no cartilage for a matrix-anabolic mechanism to act on. Inflammatory and crystal arthritis are driven by processes the proposed mechanism does not touch.

Discontinuation & Cycling

• Intended duration: Cartalax is presented as a course-based intervention rather than a lifelong one. Circulating protocols run 10–20 days and stop, on the premise that a transcriptional effect persists after the peptide is cleared.

• Withdrawal effects: None have been reported or studied. No physiological dependence mechanism is plausible for a tripeptide cleared within minutes, and no published account describes rebound symptoms after a course ends.

• Tapering: No taper is described in any circulating protocol and none has a rationale. Courses are stopped abruptly at the planned end date, which is consistent with the absence of any accumulation or receptor down-regulation.

• Cycling for efficacy: Cycling is the standard practice, with two to three courses per year and multi-month gaps. No study has compared cycled with continuous use, so the interval reflects convention and exposure caution rather than measured tolerance.

Sourcing and Quality

• Regulatory reality of the source: No pharmacy-grade Cartalax exists outside Russia. Every Western supplier ships it labelled “research use only, not for human consumption”, which places all identity, purity and sterility responsibility on the buyer.

• What to look for: A batch-specific certificate of analysis with mass spectrometry confirming the Ala-Glu-Asp sequence, high-performance liquid chromatography purity above 98%, endotoxin below 0.5 endotoxin units per milligram, and a sterility statement.

• Third-party testing: Vendor-supplied certificates are not third-party testing. Independent verification means a certificate issued by an accredited laboratory unaffiliated with the seller, ideally with the buyer’s own lot submitted for confirmatory analysis.

• Formulation considerations: Two distinct products share the name: freeze-dried synthetic tripeptide for reconstitution, and oral capsules of the cartilage polypeptide complex. They are not interchangeable, and the oral extract is not the synthetic tripeptide.

• Compounding pharmacies: No United States compounding pharmacy legitimately supplies Cartalax, because it is not on the Food and Drug Administration’s list of bulk substances permitted in compounding. Any pharmacy offering it is operating outside that framework.

Practical Considerations

• Time to effect: Unknown. No study has measured onset of any human effect. Circulating protocols imply assessment after a full 10–20 day course plus several weeks, which means at least two months before any judgement is possible.

• Common pitfall, stacking: Starting Cartalax alongside collagen, glucosamine or a new exercise programme makes attribution impossible. Because the expected effect size is unquantified, only a single-variable change can produce interpretable information.

• Common pitfall, assuming purity: Buyers routinely treat a vendor certificate as verification. Analyses of the same supply channel show label claims diverging from measured content by an order of magnitude, so unverified purity is the default assumption.

• Regulatory status: Cartalax has no marketing authorisation in the United States, European Union or United Kingdom. It is not an approved drug, not a lawful dietary supplement ingredient, and not available by prescription or off-label use.

• Cost and accessibility: Vials cost roughly 40 to 90 US dollars, so cost is not the barrier. Accessibility is constrained instead by legality and by the absence of any verified supply route.

• Structural funding asymmetry: No one can patent a tripeptide, so no manufacturer recovers trial costs, and insurers and national health systems have no incentive to fund evidence for a product they will never reimburse. That asymmetry, not a negative result, explains the missing trials.

Interaction with Foundational Habits

• Sleep: Direction is none documented. No sedative or stimulant property has been reported for Cartalax, and no study has measured sleep architecture. The related peptide epitalon is claimed to act on the pineal gland, but that mechanism is not attributed to the cartilage tripeptide, so no timing adjustment around bedtime has any basis.

• Nutrition: Direction is potentially blunting for oral use. Dietary protein floods the intestinal peptide transporter with competing di- and tripeptides, so an oral course taken with a high-protein meal would face competition for absorption. Circulating protocols place oral dosing on an empty stomach, which is consistent with that mechanism though untested.

• Exercise: Direction is potentially potentiating, by mechanism only. Progressive loading is the intervention with the strongest evidence for cartilage health, and mechanical loading and matrix-gene activation act on the same chondrocyte programme Cartalax is proposed to influence. No study has combined them, and Cartalax is no substitute for loading.

• Stress management: Direction is indirect. Cartalax has no documented effect on cortisol or the stress response, and no study has measured either. The relevant interaction runs the other way: chronic stress raises inflammatory signalling that works against the anti-inflammatory shift claimed for the peptide in culture.

Monitoring Protocol & Defining Success

Because no validated response marker exists for Cartalax, monitoring serves two purposes rather than one: establishing a defensible pre-treatment baseline, and catching harm from an unverified injectable. Baseline testing before a first course covers inflammatory markers, cartilage turnover markers, kidney and liver panels, a complete blood count, serum IGF-1 and vitamin D status, together with a recorded pain and function score and, where joint symptoms are the target, current imaging. Ongoing testing follows a fixed cadence: the complete blood count and inflammatory markers again at 2 weeks, the full panel at 3 months, then every 6 to 12 months while courses continue. Any fever or spreading injection-site reaction triggers immediate testing outside that schedule rather than waiting for the next timepoint.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
hs-CRP	Below 1.0 mg/L	Systemic inflammatory load that accelerates cartilage loss	hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker. Conventional labs call anything below 3.0 mg/L normal, a far looser target. No fasting needed; repeated if any infection occurred within two weeks
ESR	Below 15 mm/h (men), below 20 mm/h (women)	Separates degenerative joint pain from inflammatory arthritis	ESR is erythrocyte sedimentation rate, how fast red cells settle. Best paired with hs-CRP; rises with anaemia and with age independently of joint disease
Serum COMP	No established target; track change from the individual’s own baseline	Reflects cartilage matrix turnover, the process the peptide is proposed to shift	COMP is cartilage oligomeric matrix protein. Assays are not standardised across laboratories, so a single laboratory throughout is required. Samples are drawn before exercise, which raises it acutely
Urinary CTX-II	No established target; track change from the individual’s own baseline	Direct readout of type II collagen breakdown in cartilage	CTX-II is C-telopeptide of type II collagen. Measured on the second morning void and normalised to urinary creatinine. Conventional care sets no reference range for it
Serum IGF-1	120–200 ng/mL, interpreted against age-specific norms	Baseline for the unresolved growth-signalling concern	IGF-1 is insulin-like growth factor 1. Fasting preferred. A pre-treatment value is what makes any later rise interpretable
25-hydroxyvitamin D	40–60 ng/mL	Identifies a correctable nutritional driver of joint and bone symptoms	Conventional labs accept 30 ng/mL as sufficient. No fasting needed; paired with serum calcium and parathyroid hormone when the result is low
eGFR	Above 90 mL/min/1.73 m²	Organ-function baseline before any self-sourced injectable	eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering. Conventional concern begins below 60. No fasting needed; ordered with a full metabolic panel
Complete blood count with differential	Within laboratory reference range	Detects infection or marrow suppression after injections from unverified sources	Repeated urgently alongside hs-CRP if fever or injection-site redness follows a dose. No fasting needed

Qualitative markers matter more here than usual, because the objective endpoints are slow and the validated ones absent:

• Joint pain at rest and on loading, scored 0 to 10 on the same activity each week
• Morning stiffness duration in minutes, recorded on waking
• Stair descent and floor-to-stand ability, the functions that degrade first in knee and hip osteoarthritis
• Energy and recovery after training sessions of comparable load
• Sleep quality, since disturbed sleep both amplifies pain perception and confounds it

Emerging Research

• No registered trial of Cartalax: A ClinicalTrials.gov search on 2026-09-01 for Cartalax, Kartalax and Ala-Glu-Asp returned no study of this compound, in any phase, anywhere. The evidence gap is registration-level, not merely publication-level.

• Peptide injection for osteoarthritis, an adjacent benchmark: NCT07225829 is a phase 2a randomised, double-blind, placebo-controlled trial of intra-articular 4P004 in 129 participants with knee synovitis (inflammation of the joint lining) and osteoarthritis, with pain at week 4 as its primary endpoint. Cartalax has no equivalent.

• Matrix-directed comparator trial: NCT04998188 is comparing intra-articular hydrolysed collagen against placebo in 204 participants with knee osteoarthritis, with a pain score at six months as its primary endpoint. It sets the standard Cartalax claims would have to meet.

• Research that could strengthen the case: Chondrocyte senescence is now an accepted target in osteoarthritis pathogenesis (Myakisheva et al., 2023). If senescence-directed agents show clinical benefit, the mechanistic premise behind Cartalax gains external support.

• Research that could weaken the case: Intestinal handling studies show most tripeptides are hydrolysed rather than absorbed intact, and that this is structure-dependent (Rohm et al., 2019). Direct measurement of Ala-Glu-Asp absorption could remove the oral route entirely.

• Independent replication is the decisive variable: The nearest thing to outside work on this peptide family comes from Italian groups reporting senescence-marker effects, and the developing institute co-authored even that (Sinjari et al., 2020). Replication of the cartilage-specific findings by a group with no commercial interest would change the picture most.

Conclusion

Cartalax is a three-amino-acid peptide designed as a cartilage-directed signal within a Russian family of very short peptides. What can be said with confidence is narrow. In laboratory dishes of aged human cells, it shifts the activity of genes tied to cartilage building and to cellular aging, and it does so at very low concentrations. What cannot be said covers almost everything that would matter to a decision: no controlled study in people has measured joint pain, joint function, cartilage thickness or any other outcome a person would notice, and none has measured safety.

The evidence base is also unusually concentrated. Nearly all of it comes from one institute that both developed the compound and profits from selling it, and the small amount of outside work has examined the same laboratory measures rather than people. That is not grounds for dismissing the findings, but it does mean they have not been reproduced by parties without a stake in the outcome. Nor is there any commercial or institutional sponsor positioned to fund a proper trial of an unpatentable molecule that no health system will pay for.

For someone willing to act on thin evidence where the downside looks small, the practical picture is that the biological reasoning is coherent and the human evidence is absent, while the most concrete documented hazard is not the molecule but the unregulated market supplying it, where the contents of a vial frequently bear little relation to its label.

Top - Benefits - Risks - Protocol